Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06664151 · ClinicalTrials.gov registry record · Early Phase 1
A Phase 0 Window of Opportunity Trial of Intratumoral Seasonal Influenza Immunization in Cutaneous Squamous Cell Carcinoma (CSCC) Patients Awaiting Curative Excision
A Early Phase 1 study of Skin Cancer and Cutaneous Squamous Cell Carcinoma (CSCC), sponsored by Dana-Farber Cancer Institute.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 25
- Enrollment target
- 2
- Study locations
NCT06664151: Recruiting Early Phase 1 study of Skin Cancer and Cutaneous Squamous Cell Carcinoma (CSCC), sponsored by Dana-Farber Cancer Institute.
NCT06664151 is a Early Phase 1 study of Skin Cancer and Cutaneous Squamous Cell Carcinoma (CSCC) that is actively recruiting participants, run by Dana-Farber Cancer Institute. The registered enrollment target is 25 participants, below the 464-participant average among 40 other Skin Cancer trials with a reported enrollment target (95% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06664151, a Early Phase 1 study of Skin Cancer and Cutaneous Squamous Cell Carcinoma (CSCC), is actively recruiting participants, sponsored by Dana-Farber Cancer Institute.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 25 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study is investigating the effects on immune cells of injecting the influenza vaccine (also known as "flu shot") into cutaneous squamous cell carcinoma (CSCC) tumors prior to having standard-of-care Mohs excision surgery. The study will help understand if the addition of the influenza vaccine could improve the immune system response against the cancer. The names of the study drug involved in this study is: -Fluzone Influenza vaccine (flu shot)
Primary Outcome
CD8+ T-cell infiltration density (as measured by cells/mm2) on tumors is collected at the time of Mohs micrographic surgery compared to baseline (time of diagnostic biopsy).
Conditions Studied
Interventions
- BIOLOGICAL Fluzone Trivalent
Study Locations (2)
Massachusetts
- Brigham and Women's Hospital - Boston
- Dana-Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2024-11-26 |
| Est. Completion | 2026-08-30 |
| Phase | Early Phase 1 |
What NCT06664151 shows while recruiting
NCT06664151 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 464-participant average among 40 other Skin Cancer trials with a reported enrollment target (95% lower).
The record links to 3 conditions, with Skin Cancer appearing as the primary indexed condition, and to 1 intervention - of which Fluzone Trivalent is the first listed.
NCT06664151 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT06664151 about?
NCT06664151 is a clinical study titled "A Phase 0 Window of Opportunity Trial of Intratumoral Seasonal Influenza Immunization in Cutaneous Squamous Cell Carcinoma (CSCC) Patients Awaiting Curative Excision". This study is investigating the effects on immune cells of injecting the influenza vaccine (also known as "flu shot") into cutaneous squamous cell carcinoma (CSCC) tumors prior to having standard-of-care Mohs excision surgery. The study will help understand if the addition of the influenza vaccine c...
What is the current status of trial NCT06664151?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 25 participants. The study started on 2024-11-26. Estimated completion is 2026-08-30.
What conditions does trial NCT06664151 study?
This clinical trial studies the following conditions: Skin Cancer, Cutaneous Squamous Cell Carcinoma (CSCC), Cutaneous Squamous Cell Cancer.
What interventions are being tested in trial NCT06664151?
The interventions under investigation include: Fluzone Trivalent (BIOLOGICAL).
Who is sponsoring clinical trial NCT06664151?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06664151 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Skin Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06664151's enrollment target sits among peer trials
25 35th of 40 higher than 6 of 40 other Skin Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Skin Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Pilot Trial of Supplemental Vitamin A and Nicotinamide
RECRUITING · Early Phase 1
-
Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma
ACTIVE NOT RECRUITING · Early Phase 1
-
Rural Adult and Youth Sun Protection Study
RECRUITING · NA
-
TIL Therapy in cSCC and MCC
RECRUITING · Phase 2
-
Liquid Biomarker Study in Melanoma and Non-Melanoma Skin Cancers
RECRUITING
-
Undergraduate Skin Cancer Prevention Trial
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI